Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 8/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818042 | 1.00 | CYP11B2 (0.45) | CYP11B2MAPK1IDO1CYP11B1RBP4 | |
| SCHEMBL13475350 | 1.00 | CYP11B2 (0.45) | CYP11B2MAPK1IDO1CYP11B1RBP4 | |
| SCHEMBL13475349 | 1.00 | CYP11B2 (0.45) | CYP11B2MAPK1IDO1CYP11B1RBP4 | |
| SCHEMBL2820626 | 0.88 | CYP11B2 (0.46) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 | |
| SCHEMBL2820579 | 0.88 | CYP11B2 (0.46) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 | |
| SCHEMBL2820670 | 0.88 | CYP11B2 (0.46) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 | |
| SCHEMBL2817732 | 0.88 | CYP11B2 (0.46) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 | |
| SCHEMBL13475345 | 0.88 | CYP11B2 (0.46) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 | |
| SCHEMBL9493469 | 0.87 | CYP11B2 (0.45) | CYP11B2MAPK1IDO1CYP11B1RBP4 | |
| SCHEMBL9777311 | 0.84 | CYP11B2 (0.43) | CYP11B2MAPK1IDO1CYP11B1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP11B2 6/4885MAPK1 977/4885IDO1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.